FINWIRES · TerminalLIVE
FINWIRES

AECOM's Fiscal Q2 Beat Supported by Americas Strength, AI Gains, RBC Says

By

AECOM (ACM) delivered a modest earnings beat in fiscal Q2, with results slightly ahead of consensus as strong performance in the Americas offset softer international trends impacted by geopolitical disruption in the Middle East, RBC Capital said in a note Tuesday.

The analyst said constant-currency revenue growth was driven by strong execution in the Americas, while international operations declined due to regional headwinds, though margins expanded year over year on efficiency gains and early AI-driven productivity and win-rate improvements.

RBC pointed to record backlog growth across both the Americas and international segments, supporting stronger visibility into future demand, while management raised fiscal 2026 earnings per share guidance and reaffirmed long-term targets driven by steady demand in transportation, water, and environmental services.

The note also said AECOM's shift toward higher-margin advisory and program management services, along with growing opportunities in PFAS remediation as it builds capabilities to support long-term environmental cleanup demand.

RBC maintained its outperform rating on the stock and lowered its price target to $111 from $142.

Price: $69.92, Change: $-0.03, Percent Change: -0.05%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP